The FDA has accepted the NDA for paltusotine for the treatment and long-term maintenance of acromegaly in adults.

SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for ...

Patients with acromegaly make too much growth hormone, which causes them to grow disproportionately large bones, organs and ...

Sandostatin (octreotide acetate) is a prescription drug used to treat acromegaly and other conditions. Sandostatin can cause side effects that range from mild to serious. Examples include diarrhea ...

Pharmaceuticals announced the U.S. Food and Drug Administration, FDA, accepted its New Drug Application, NDA, for ...

In Phase 3 studies, once-daily, oral paltusotine maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1 ...

has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults. Paltusotine, previously known as CRN00808, is an orally ...

Paltusotine was granted Orphan Drug Designation for the treatment of acromegaly by the FDA in July 2020. This designation is provided to drugs defined as being intended for the safe and effective ...